股市情绪偏暖，债市情绪有所企稳

1. Report Industry Investment Rating No relevant content provided. 2. Core Views of the Report - The sentiment in the stock market is warm, and the sentiment in the bond market has stabilized. For stock index futures, policies are starting to focus on manufacturing profits. For stock index options, a covered defense strategy is recommended. For treasury bond futures, the bond market sentiment has shown signs of stabilization [1][2]. 3. Summary by Relevant Catalogs 3.1 Market Views Stock Index Futures - View: Policies are starting to focus on manufacturing profits. New hot themes are emerging, with the Hengke Innovation Pharmaceutical Index excluding CXO companies and photovoltaic glass promoting production cuts, accelerating capacity clearance and driving up the pharmaceutical and non - ferrous industries. The Central Financial and Economic Commission meeting emphasizes anti - "involution" in some manufacturing industries, which may boost the inflation chain. In the context of mid - year report announcements, attention to pre - announced performance increases may be strengthened. In a warm - sentiment environment, long positions should be maintained, and IM long positions are recommended [1][5]. - Operation Suggestion: Allocate IM long positions [5]. - Market Outlook: Oscillating with an upward bias [5]. Stock Index Options - View: A covered defense strategy is recommended. The trading volume in the options market has been continuously declining, and the trading liquidity is lower than expected. In a low - liquidity derivatives market, sentiment indicators show synchronicity rather than guidance, and the average implied volatility of each option variety has decreased by 0.52%. Given the low liquidity and volatility and the ineffective guidance of sentiment indicators, and the resistance level above the index, a covered defense strategy is advisable [1][5]. - Operation Suggestion: Covered defense [5]. - Market Outlook: Oscillating [5]. Treasury Bond Futures - View: The bond market sentiment has stabilized. After recent adjustments, the bond market sentiment stabilized yesterday. The central bank continued net capital injection, with a net injection of 305.8 billion yuan through reverse repurchase operations. The overall funding situation has eased, and the DR007 rate has slightly declined. The policy announced by the National Development and Reform Commission was in line with expectations, and the stock - bond seesaw effect has weakened. The market may be pre - gambling on June PMI data and the central bank's bond - buying restart. However, caution should still be exercised, and attention should be paid to June PMI data and central bank operations [2][5][6]. - Operation Suggestion: Trend strategy: Oscillating. Hedging strategy: Pay attention to short - position hedging at low basis levels. Basis strategy: Appropriately pay attention to basis widening. Curve strategy: Steepening the yield curve in the medium - term has higher odds [6]. - Market Outlook: Oscillating [5][6]. 3.2 Economic Calendar - China's official manufacturing PMI for June was 49.7, up from the previous value of 49.5. The final value of the US Markit manufacturing PMI for June was 52.9, higher than the previous and predicted values of 52. The US unemployment rate and non - farm payrolls for June are yet to be announced [7]. 3.3 Important Information and News Tracking - Domestic Macroeconomics: From January to May, the added value of large - scale electronic information manufacturing enterprises increased by 11.1% year - on - year, 4.8 and 1.6 percentage points higher than the overall industry and high - tech manufacturing respectively. In May, the added value increased by 10.2% year - on - year. Mobile phone production was 570 million units, a year - on - year decrease of 6.5%, with smartphone production at 450 million units, a 2.1% decrease. Microcomputer equipment production was 130 million units, a 5.5% increase, and integrated circuit production was 193.5 billion pieces, a 6.8% increase [7]. - Pharmaceutical Industry: The National Healthcare Security Administration and the National Health Commission issued measures to support the high - quality development of innovative drugs, including supporting the use of healthcare insurance data for innovative drug R & D, strengthening information sharing among medical, healthcare insurance, and pharmaceutical sectors, and providing necessary healthcare insurance data services for innovative drug R & D on the premise of data security and compliance [8].